Aadi Bioscience, Inc

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company with a focus on precision therapies for genetically-defined cancers. The company leverages precision medicine and nanoparticle technology to maximize the potential of mTOR inhibition, aiming to offer transformative therapies to cancer patients with mTOR pathway driver alterations. Their lead product has received FDA approval for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa). Aadi's leadership team consists of industry veterans from top biotech companies with a track record of bringing novel cancer therapies to market. The company's science-first mindset and patient-centric approach align with its commitment to developing products for cancers with mTOR pathway driver alterations. Founded in 2011, Aadi Bioscience is headquartered in the United States. The company recently received a $72.50M Post-IPO Equity investment on 22 September 2022 from notable investors including Acuta Capital, Avoro Capital, KVP Capital, Alerce Medical Technology Partners, and Acorn Capital Advisors. For more information, please visit Aadi Bioscience.